Adverse reactions to XXXX . Analysis of 921 reports.

@entity1 @entity6616 @entity137 @entity16 @entity409 @entity1503 @entity358 @entity56 @entity1030 @entity401 @entity293
Reports on adverse reactions to @entity6616 today are common in Sweden and constitute 10 to 12 percent of all incoming reports. We present an analysis of 921 reports of adverse reactions received by the Swedish @entity137 Committee during the period 1966--1976. The two largest groups consist of reports of @entity358 (43 percent) and @entity56 (42 percent). The remaining reports fall into any of four smaller groups, chronic pulmonary reactions, @entity409 , @entity1503 or @entity16 . Acute @entity56 in all aspects are very similar and carry the characteristics of an acute @entity56 reaction. The increasing number of reports--even in relation to sales figures--would be best explained by a continuous sensitization. @entity1030 ( @entity401 ) afflict older @entity1 , often after prolonged treatment with relatively small doses. We suggest that these reactions are elicited by a toxic mechanism. Seventy-one percent of all reactions were severe enough to cause the @entity1 's hospitalization; only 1 percent was fatal. The risk of an adverse reaction varies with sex and age, increases with age and is higher in @entity1 than in @entity1 . The time has come for a re-evaluation of @entity6616 and its role in the treatment of @entity293 .
